Table 4 Initial treatment pattern for MIUBC patients in routine clinical practice.
From: PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer
Variable | Total |
|---|---|
(N = 229) | |
n (%) | |
Systemic/intravesical therapy | 50 (21.8) |
Therapy type (not mutually exclusive) | 50 |
Systemic therapy | 29 (58.0) |
Intravesical therapy | 26 (52.0) |
Treatment status (not mutually exclusive) | 50 (21.8) |
Neo-adjuvant | 5 (10.0) |
PD-1/PD-L1 inhibitors | 2 (40.0) |
Chemotherapy | 5 (100.0) |
Adjuvant | 11 (22) |
Pd-1/Pd-L1 inhibitors | 7 (63.6) |
Chemotherapy | 9 (81.8) |
Other (unknown) | 1 (9.1) |
Medication therapy alone (not combined with surgery) | 14 (28) |
PD-1/PD-L1 inhibitors | 6 (42.9) |
Chemotherapy | 12 (85.7) |
Intravesical chemotherapy | 26 (52) |
Epirubicin/pirarubicin | 9 (34.6) |
BCG vaccine | 2 (7.7) |
Gemcitabine | 8 (30.8) |
Lobaplatin | 14 (53.8) |
Any cystectomy or transurethral bladder resection for previous and planned surgery | 226 |
Transurethral bladder resection only, no partial or radical cystectomy | 33 (14.6) |
Partial cystectomy, with/without transurethral bladder resection | 5 (2.2) |
Radical cystectomy, with/without transurethral bladder resection | 185 (81.9) |
Partial and radical cystectomy, with/without transurethral bladder resection | 3 (1.3) |
